Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
Its a major breakthrough for women’s ovarian cancer care in Europe
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Subscribe To Our Newsletter & Stay Updated
